ClinicalTrials.gg
Not yet recruitingNCT06966531Updated May 12, 2025

Prevalence of Myocarditis in Patients Suspected Myocardial Infarction With Non-Obstructive Coronary Arteries

An observational study in Prevalence of Myocarditis in MINOCA Patients, sponsored by Assiut University. Not yet recruiting. Open to participants aged 17 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-12.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
148
Ages
17 Years to 80 Years
Sex
All
01

Study summary

This study aims to determine the prevalence of myocarditis among patients suspected of having myocardial infarction with non-obstructive coronary arteries (MINOCA) and to analyze its clinical characteristics, diagnostic markers .

Read the detailed description

Acute myocardial infarction (AMI) remains the leading causes of high morbidity and mortality worldwide, Recently, a distinct population with myocardial infarction with nonobstructive coronary arteries (MINOCA) has been increasingly recognized because of the widespread use of coronary angiography. MINOCA occurs in 5%-10% of all AMI and they are younger and more often women compared to patients with AMI and obstructive coronary artery disease (CAD) , The underlying causes of MINOCA are manifold and may include plaque rupture or erosion, thromboembolism, coronary spasm, spontaneous dissection, microvascular dysfunction and supply/demand mismatch. Some non-ischemic diseases such as myocarditis may also mimic the presentation of MINOCA .Of note, several studies have found that the prognosis of MINOCA is not trivial and patients are still at considerable risks for long-term adverse cardiovascular (CV) events despite the optimal secondary prevention treatments [[6], [7], [8], [9], [10]]. Thus, it is of necessity and profound implications to find potential residual risk factors and improve prognosis in MINOCA population.

Myocarditis is commonly caused by viral infections, but it can also be caused by bacterial infections, toxic substances, or autoimmune disorders . Myocarditis is more common in younger patients, although it affects patients of all ages. Fulminant myocarditis, although rare, can result in life-threatening cardiogenic shock . Diagnosis of myocarditis is made using CMRI characterized by the presence of diffuse myocardial edema on T2 and with myocardial biopsy . In a meta-analysis of five observational studies with available CMRI data, one-third of MINOCA patients had myocarditis. It was more common in younger patients and those with high C-reactive protein .

02

Conditions studied

  • Prevalence of Myocarditis in MINOCA Patients

Browse trials for

Keywords

  • Myocarditis
  • MINOCA
  • Normal coronary angiography
03

In context

Myocarditis

174 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

This study's planned enrollment of 148 is below the median of 208 across 120 observational studies indexed under Myocarditis.

Browse Myocarditis studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Study Population Description Myocardial infarction patients who were underwent PPCI and the coronary angiography showing insignificant lesions (stenosis less than 50% )

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients; diagnosed with myocardial infarction with nonobstructive coronary arteries (MINOCA)
  • clinical symptoms
  • : ischemic changes with or without ST segment elevation
  • Echocardiograpy : segmental wall motion abnormalities (SWMA)
  • positive cardiac enzymes
  • Coronary angiography: insignificant lesions ,the absence of culprit obstructive coronary artery disease (epicardial coronary artery stenosis ≥50%)

Exclusion criteria

Exclusion Criteria:

  • Significant coronary artery disease (>50% stenosis) on angiography.
  • Prior history of myocarditis or cardiomyopathy.
  • to CMR (e.g., pacemakers, severe renal dysfunction).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
148 participants (estimated)
Patient registry
No

Groups and cohorts

  • MINOCA

    Acute Myocardial infarction patient with non obstructive coronary arteries

    Procedure: Coronary angiography

Interventions

  • ProcedureCoronary angiography

    distinguish between true MI with significant lesion and MINOCA with insignificant lesions (less than 50%)

06

What researchers measure

Primary outcomes

  1. Prevalence of myocarditis in patients presenting with MINOCA, as diagnosed by CMR.

    Studying The incidence of myocarditis in MINOCA patients

    Time frame: 1 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Mar 2027, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2025
First posted
May 12, 2025
StartEst.
May 5, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Apr 1, 2027
Last update
May 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06966531
Lead sponsor
Assiut University
Responsible party
Ahmed Gamal Thabit Mohamed (Resident , department of Cardiology،Principal Investigator, Assiut University) — Principal investigator
First posted
May 12, 2025
Start date
May 5, 2025 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
May 12, 2025

Study contacts

Ahmed Gamal Thabit Mohamed
Contact
ahmedgamal54011@gmail.com
+201065476011
Ayman khairy Mohamed Hassan
principal investigator · Cardiology department
Khaled Mohamed Abdullah Mohamed
principal investigator · Cardiology department

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion